A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects With Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination With Pembrolizumab in Subjects With Advanced Gastrointestinal Tumors
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2018
At a glance
- Drugs CGX 1321 (Primary) ; Pembrolizumab
- Indications Colorectal cancer; Gastrointestinal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Curegenix
- 09 Apr 2018 Phase 1b portion of the study added: Study of CGX1321 in combination with pembrolizumab in subjects with advanced gastrointestinal tumors and advanced colorectal tumors.
- 09 Apr 2018 Planned number of patients changed from 71 to 72.
- 09 Apr 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2020.